PRUVN Reveals Human Clinical Trial Results of Max International's RiboCeine™ Supplementation's Impact on Serum Glutathione Levels
LOS ANGELES, April 25, 2024 /PRNewswire/ -- PRUVN Research LLC, [PRUVN], a leading research organization validating wellness products and services, is excited to announce the results of its recent preliminary study with Max International, investigating the impact of RiboCeine™ supplementation on serum glutathione levels. Glutathione, the master antioxidant in cellular defense against oxidative stress, has garnered significant awareness in the wellness and longevity industry for its potential health benefits with more than 180,000 research articles on glutathione currently listed on the US National Library of Medicine database.
- For the past three decades, researchers have conducted 55 peer-reviewed, independent clinical studies on Max International's patented "cornerstone" compound, primarily using animal models.
- However, recognizing the need for human clinical trials to further their findings, Max International turned to PRUVN to embark on this next research phase.
- The study further analyzed the impact of age on glutathione levels by dividing participants into two age groups: 38-50 and 51-60.
- The placebo group exhibited a decrease in serum glutathione levels across all age groups, with a higher drop in older participants.